[Federal Register Volume 89, Number 55 (Wednesday, March 20, 2024)]
[Notices]
[Pages 19855-19856]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-05878]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Manufacturing 
of Anti-Malaria Monoclonal Antibody L9LS in Transgenic Cows and Sheep

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institute of Allergy and Infectious Diseases, an 
institute of the National Institutes of Health, Department of Health 
and Human Services, is contemplating the grant of an Exclusive Patent 
License to practice inventions embodied in the Patents and Patent 
Applications listed in the Supplementary Information section of this 
Notice to Taurgen Malaria, Inc. (``Taurgen''), headquartered in Logan, 
UT. Taurgen Malaria, Inc. is a wholly-owned subsidiary of Taurgen 
Therapeutics, LLC, which is also headquartered in Logan, UT.

[[Page 19856]]


DATES: Only written comments and/or applications for a license which 
are received by the National Institute of Allergy and Infectious 
Diseases' Technology Transfer and Intellectual Property Office on or 
before April 4, 2024 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
and comments relating to the contemplated Exclusive Patent License 
should be directed to: Wade Green, Ph.D., Lead Technology Transfer and 
Patent Specialist, Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases 
Telephone: (301) 761-7505; Email: [email protected].

SUPPLEMENTARY INFORMATION:

Intellectual Property

    1. United States Provisional Patent Application No. 62/842,590, 
filed May 03, 2019, titled ``Neutralizing antibodies to Plasmodium 
falciparum circumsporozoite protein and their use'' [HHS Reference No. 
E-087-2019-0-US-01];
    2. International Patent Application No. PCT/US2020/031345, filed 
May 04, 2020, titled ``Neutralizing antibodies to Plasmodium falciparum 
circumsporozoite protein and their use'' [HHS Reference No. E-087-2019-
0-PCT-01];
    3. European Patent Application No. 20727798.9, filed May 04, 2020, 
titled ``Neutralizing antibodies to Plasmodium falciparum 
circumsporozoite protein and their use'' [HHS Reference No. E-087-2019-
0-EP-02]; and
    4. United States Patent Application No. 17/608,381, filed October 
02, 2021, titled ``Neutralizing antibodies to Plasmodium falciparum 
circumsporozoite protein and their use'' [HHS Reference No. E-087-2019-
0-US-03].
    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States of America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to the following:
    ``Production of the L9LS monoclonal antibody in transgenic bovine 
and ovine species.''
    The E-087-20219 patent family is primarily directed to (1) 
compositions of matter of the L9LS monoclonal antibody, (2) methods of 
treating and preventing infection with Plasmodium falciparum using the 
L9LS monoclonal antibody, and (3) methods of manufacturing the L9LS 
monoclonal antibody. The exclusive field of use which may be granted to 
Taurgen applies to only manufacturing of the L9LS monoclonal antibody 
in transgenic bovine and ovine species. Accordingly, the proposed scope 
of rights which may be conveyed under the license covers only a portion 
of total scope of the E-087-2019 patent family and only a subset of the 
possible methods of manufacturing the L9LS monoclonal antibody.
    This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published Notice, the National 
Institute of Allergy and Infectious Diseases receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 
404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially and may be made 
publicly available.
    Complete license applications submitted in response to this Notice 
will be presumed to contain business confidential information and any 
release of information from these license applications will be made 
only as required and upon a request under the Freedom of Information 
Act, 5 U.S.C. 552.

    Dated: March 14, 2024.
Surekha Vathyam,
Acting Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-05878 Filed 3-19-24; 8:45 am]
BILLING CODE 4140-01-P